ClinicalTrials.gg
Not yet recruitingNCT07950215Updated Nov 20, 2026

A Phase III Study of AND017 to Evaluate Efficacy and Safety in NDD-CKD Associated Anemia

A Phase 3 interventional study of AND017 capsules and ESA in Anemia Due to Chronic Kidney Disease, sponsored by Kind Pharmaceuticals LLC. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Kind Pharmaceuticals LLC · Phase 3, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of AND017 in non-dialysis-dependent (NDD)-CKD patients with anemia compared with the active control, erythropoietin stimulating agents (ESA).

02

Conditions studied

  • Anemia Due to Chronic Kidney Disease

Browse trials for

Keywords

  • Anemia
  • HIF-PHI
  • CKD
  • NDD-CKD
  • Renal anemia
03

In context

Anemia

1,812 studies on the registry are indexed under Anemia; 211 are open to participants now.

This study's planned enrollment of 240 is above the median of 117 across 1,336 interventional studies indexed under Anemia.

Browse Anemia studies →

Lead sponsor

Kind Pharmaceuticals LLC is the lead sponsor of 11 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of providing signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Body weight from 45-140 kg inclusive.
  • A diagnosis of CKD confirmed at screening, CKD stage 3, 4, or 5 defined by \<60 mL/min/1.73 m2.
  • Prior ESA use and levels:

    1. ESA-naïve: Defined as no use of any ESA treatment for at least 12 weeks before randomization; Mean of the two most recent Hb values during the screening period obtained at least 7 days apart must be ≥7.5 g/dL and \<10.0 g/dL.
    2. ESA-treated: Defined as having received an approved ESA, administered intravenously or subcutaneously, for at least 6 weeks prior to randomization, with no change in ESA product and no treatment interruption exceeding two consecutive weeks; Mean of the two most recent Hb values during the screening period obtained at least 7 days apart must be 9.0-11.0 g/dL inclusive.
  • TSAT ≥20% or ferritin ≥100 ng/mL at screening test.
  • Serum folate and vitamin B12 ≥ lower limit normal (LLN) at screening test
  • Total ≤1.5× upper limit normal (). For Gilbert's Syndrom, \<3×ULN.
  • (AST) and alanine aminotransferase (ALT) ≤3×ULN
  • No evidence of other causes of anemia caused by a pathologic process in the hematopoietic system, including intra- or extravascular hemolysis, or myelodysplasia
  • No other primary cause for anemia other than CKD.

Exclusion criteria

Exclusion Criteria:

  • Concurrent retinal neovascular lesions requiring treatment including proliferative diabetic retinopathy, exudative age-related macular degeneration, retinal vein occlusion, macular edema, etc.
  • Chronic inflammatory disease other than glomerulonephritis that could impact erythropoiesis or concurrent disease with inflammatory symptoms.
  • History of gastric/intestinal resection considered to affect the absorption of drugs in the gastrointestinal tract or concurrent symptomatic gastroparesis despite being on treatment.
  • bleeding within 4 weeks of first dose; bleeding diathesis or risk of bleeding that has not been medically or surgically corrected at least 4 weeks prior to first dose of study drug.
  • History or concurrent hemosiderosis, hemochromatosis or hyper-coagulable condition.
  • Uncontrolled hypertension, defined as patients with hypertension having more than one of three systolic blood pressure (SBP) >180 mmHg, or diastolic blood pressure (DBP) >110 mmHg during the screening period.
  • History of stroke, , myocardial infarction, thromboembolic event , pulmonary embolism, or lung infarction within 24 weeks before the screening assessment.
  • Participants with a history of significant liver disease or active liver disease.
  • History of a seizure disorder or any occurrence of seizures in the past.
  • History or concurrent , except for cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell carcinoma, cervical cancer in situ.
  • History of a seizure disorder or any occurrence of seizures in the past.
  • History or concurrent malignancy, except for cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell carcinoma, cervical cancer in situ.
  • Having undergone blood transfusion and/or a surgical procedure that caused major blood loss within 8 weeks before the screening assessment
  • Participants that have major surgery planned during the study period.
  • Any prior functioning organ transplant or a scheduled organ transplantation, or anephric.
  • Serum albumin (ALB) \< 2.5 g/dL at screening test.
  • Positive for surface antigen or anti- virus antibody at the screening assessment, or positive for in a past test.
  • Having received any drug in an interventional clinical trial within 5 weeks before the randomization.
  • A known history of allergic reactions to ESA treatment.
  • History of serious drug allergies.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    AND017

    Drug: AND017 capsules

  • Active comparator
    ESA

    Drug: ESA

Interventions

  • DrugAND017Studies of AND017AND017 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    AND017 capsules administered orally with a starting dose of 8 mg TIW for ESA naive patients or 10 mg TIW for ESA treated patients

  • DrugESA

    ESA injection and dose based on package insert and local practice

06

What researchers measure

Primary outcomes

  1. The mean Hb levels averaged over Week 25-29

    Evaluate the efficacy of AND017 for treatment of anemia in patients with NDD-CKD

    Time frame: Week 25 to Week 29

Secondary outcomes

  1. Percentage of responders over the main treatment period

    defined as patients who meet either of the following criteria: For patients with baseline Hb 9.0 g/dL: mean Hb ≥ 10.0 g/dL during Weeks 25-29 and a change from baseline ≥ -1.0 g/dL during Weeks 25-29; For patients with baseline Hb \< 9.0 g/dL: an increase in Hb from baseline ≥ 1.0 g/dL during Weeks 3-29

    Time frame: Baseline, at Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment

  2. Percentage of patients with mean Hb ≥ 10.0 g/dL averaged over Weeks 5-29

    Percentage of patients with mean Hb ≥ 10.0 g/dL averaged over Weeks 5-29

    Time frame: Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment

  3. The percentage of response visits over the entire study treatment

    Response visit is defined as after first reaching ≥ 10.0 g/dL, Hb maintained within the target range of 10.0-11.0 g/dL

    Time frame: Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment

  4. The cumulative incidence of Hb non-response over Weeks 5-29

    Non-response is defined as Hb \< 10.0 g/dL and an increase from baseline \< 1.0 g/dL

    Time frame: Baseline, Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment

  5. Change from baseline in serum iron over the entire treatment period

    Time frame: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment

  6. Change from baseline in ferritin over the entire treatment period

    Time frame: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment

  7. Change from baseline in transferrin over the entire treatment period

    Time frame: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment

  8. Change from baseline in transferrin saturation over the entire treatment period

    Time frame: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment

  9. Change from baseline in total iron binding capacity over the entire treatment period

    Time frame: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment

  10. The percentage of patients received intravenous iron treatment during the entire study

    Time frame: Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment

  11. During the entire treatment period, the mean weekly dose of intravenous iron treatment (mg)

    Time frame: Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment

  12. During the entire treatment period, the time to first initiation of intravenous iron treatment (Day)

    Time frame: Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment

  13. Change from baseline in total cholesterol over the entire treatment period

    Time frame: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment

  14. Change from baseline in low density lipoprotein over the entire treatment period

    Time frame: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment

  15. Change from baseline in high density lipoprotein over the entire treatment period

    Time frame: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment

  16. Change from baseline in triglycerides over the entire treatment period

    Time frame: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Dec 2027, 10 months later.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 50. This study's planned 10 months is below that.

Counting every sponsor, half of 148 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 20, 2026
StartEst.
Feb 1, 2027
Primary completionEst.
Dec 1, 2027
CompletionEst.
Jun 1, 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950215
Lead sponsor
Kind Pharmaceuticals LLC
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Feb 1, 2027 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Yusha Zhu, M.D., Ph.D.
Contact
yusha.zhu@kindpharma.com
646-725-2552

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AND017

Start the discussion